ATE243520T1 - Durch hydroxylierung aktivierte wirkstofffreigabe - Google Patents

Durch hydroxylierung aktivierte wirkstofffreigabe

Info

Publication number
ATE243520T1
ATE243520T1 AT99905005T AT99905005T ATE243520T1 AT E243520 T1 ATE243520 T1 AT E243520T1 AT 99905005 T AT99905005 T AT 99905005T AT 99905005 T AT99905005 T AT 99905005T AT E243520 T1 ATE243520 T1 AT E243520T1
Authority
AT
Austria
Prior art keywords
hydroxylation
active release
release activated
aromatic
prodrugs
Prior art date
Application number
AT99905005T
Other languages
English (en)
Inventor
Gerard Andrew Potter
Lawrence Hylton Patterson
Lane Anstey Gynsill
Michael Danny Burke
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9802957A external-priority patent/GB2334256A/en
Application filed by Univ Montfort filed Critical Univ Montfort
Application granted granted Critical
Publication of ATE243520T1 publication Critical patent/ATE243520T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT99905005T 1998-02-12 1999-02-10 Durch hydroxylierung aktivierte wirkstofffreigabe ATE243520T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9802957A GB2334256A (en) 1998-02-12 1998-02-12 Hydroxylation activated prodrugs
US09/115,016 US20020037296A1 (en) 1998-02-12 1998-07-14 Hydroxylation activated drug release
PCT/GB1999/000416 WO1999040944A2 (en) 1998-02-12 1999-02-10 Hydroxylation activated drug release

Publications (1)

Publication Number Publication Date
ATE243520T1 true ATE243520T1 (de) 2003-07-15

Family

ID=26313102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905005T ATE243520T1 (de) 1998-02-12 1999-02-10 Durch hydroxylierung aktivierte wirkstofffreigabe

Country Status (6)

Country Link
EP (1) EP1069915B1 (de)
AT (1) ATE243520T1 (de)
AU (1) AU2531599A (de)
CA (1) CA2319837C (de)
DE (1) DE69909073T2 (de)
WO (1) WO1999040944A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4642226B2 (ja) 1998-02-06 2011-03-02 デ モントフォート ユニヴァーシティ ヒドロキシル化により活性化されたプロドラッグ
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
GB9828670D0 (en) 1998-12-24 1999-02-17 Univ Montfort Anthraquinone anticancer drugs
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
WO2010057515A1 (en) * 2008-11-21 2010-05-27 Synthon B.V. Levocetirizine by menthyl intermediate
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
KR101343443B1 (ko) * 2010-02-18 2013-12-19 재단법인 아산사회복지재단 콜키친 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
CN103524349B (zh) * 2013-10-19 2015-09-09 山东大学 Ca-4碳酸酯类衍生物、其制备方法、药物组合物与医药用途
CA3090272A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Novel small molecule drug conjugates of gemcitabine derivatives
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
CN120329323B (zh) * 2025-04-16 2026-01-13 黄冈鲁班药业股份有限公司 一种头孢吡普酯侧链的制备方法及应用
CN121517323A (zh) * 2026-01-14 2026-02-13 中国科学院长春应用化学研究所 一种基于羟基自由基的超声响应的缀合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4309344A1 (de) * 1993-03-23 1994-09-29 Gerhard Prof Dr Eisenbrand Antineoplastische Mittel mit verstärkter Wirksamkeit
EP0647450A1 (de) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen

Also Published As

Publication number Publication date
DE69909073T2 (de) 2004-05-19
WO1999040944A3 (en) 1999-09-23
CA2319837C (en) 2009-10-27
CA2319837A1 (en) 1999-08-19
AU2531599A (en) 1999-08-30
WO1999040944A2 (en) 1999-08-19
EP1069915A2 (de) 2001-01-24
DE69909073D1 (de) 2003-07-31
EP1069915B1 (de) 2003-06-25

Similar Documents

Publication Publication Date Title
ATE272040T1 (de) Durch hydroxylierung aktivierte medikamentvorstufen
DE69909073D1 (de) Durch hydroxylierung aktivierte wirkstofffreigabe
ATE438724T1 (de) Chemisch modifizierte enzymen mit mehrfachgeladenen varianten
NO20014935L (no) Middel for forbedring av ketose
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
EP1818396A3 (de) Alpha-Amylase Varianten
EP1224266A4 (de) Enzyme des auf die lysosomen gerichteten weges
EP2261200A3 (de) Modifizierte Formen von pharmakologisch aktiven Agenzien und deren Verwendung
DK1660650T3 (da) Forbedrede Sso7-polymerase-konjugat-proteiner
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
ATE493106T1 (de) Oberflächenbehandlungsmittel für dentales hartgewebe
WO2001007087A8 (en) Enzyme catalyzed anti-infective therapeutic agents
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
PT1214296E (pt) Derivados de 2-hidroxi-2-metil-3,3,3-trifluoropropanamida substituidos por n-fenilo que elevam a actividade da desidrogenase de piruvato
AU2002220697A1 (en) Isolated luciferases lu164, lual and lu22, and the use of the same
AU2002221966A1 (en) Enzyme with proteolytic activity
WO2006035445A3 (en) Methods of treating pathologies associated with oxidative stress
GB9821932D0 (en) Cytochrome P450 electrochemical system
DE69815769D1 (de) Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms
ATE418613T1 (de) Antimikrobielle zusammensetzungen
AU2003268634A1 (en) Culture having phenol oxidase-like activity
NO20014260L (no) Flerkomponentsystem for enzymkatalysert oksidasjon av substrater, og fremgangsmåter for enzymkatalysert oksidasjon
PT1289562E (pt) Novo preparado de hipericina com poli-n-vinilamidas
DE60022083D1 (de) Neutralisierungsmittel für toxin der zur gattung clostridium gehörende mikroorganismen
WO2006032809A3 (fr) Procede de detection de streptococcus agalactiae en utilisant l'activite esterase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties